News

May 19, 2025 – The FDA has approved the Novavax COVID-19 vaccine, a protein-based alternative to mRNA shots, with some limits on who can get it. The vaccine, called Nuvaxovid, is mainly intended ...
Moderna MRNA announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 vaccine, Spikevax, for use in children aged six months to 11 years, who ...
Pfizer's COVID vaccine (Comirnaty) is fully approved for patients ages 12 and up, and authorized for kids ages 6 months ...
The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., who has pushed for changes around mRNA ...
Nuvaxovid is supplied in a single-dose prefilled syringe containing 0.5mL suspension for intramuscular injection; it should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F).
The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...
Nuvaxovid includes an engineered fragment of the spike protein itself—albeit one without the genetic material that causes actual disease. It’s not a totally new approach to vaccine design.
Novavax, which makes the Nuvaxovid vaccine used to treat Covid-19, posted huge sales gains for the past three years during the height of the pandemic. But the company is now facing serious ...
NUVAXOVID’s approval is also a major milestone for the U.S. population and the healthcare industry, as it is the first and only full FDA approval for a non-mRNA, protein-based COVID-19 vaccine.
About Nuvaxovid™ (NVX-CoV2373) NVX-CoV2373 is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID.
As for Nuvaxovid, this standalone Novavax Covid-19 vaccine received its FDA approval in May, a regulatory decision that covers its use in those age 65 and older.